

**Objective:** NOTCH1 is now established to play a key role in the prognosis of several hematological malignancies. Notch proteins are multifaceted and involved in several key cellular functions with extensive crosstalk with other critical pathways; therefore, it is important to investigate NOTCH1 expression and its influence on other oncogenic pathways molecules in AML. In this pilot study, we correlated NOTCH1 and associated pathway expression patterns among childhood AML patients and correlated it with hematological parameters and overall survival (OS) data. **Methodology:** RNA from diagnostic BM biopsies (n=35) were subjected to expression analysis employing nCounter Pan-Cancer pathway panel by Nanostring technologies. Laboratory and clinical data were correlated with expression of NOTCH1 and several other oncogenic signaling pathways (n=780). nSolver software v3 and SPSS software v24.0 were utilized for statistical evaluation. Hierarchical clustering and principle component analyses were performed employing Qluore Omics Explorer v3.2. **Results:** 35 -AML patients (median age 8 yrs., range <1-18 yrs.) were dichotomized into low NOTCH1 (17/35; 49%) and high NOTCH1 (18/35; 51%) groups based on receiver operating characteristic (ROC) curve analysis (74% AUC; 82% sensitivity /68% specificity). Age, gender, hematological data or molecular risk factors (FLT3 mutation/molecular fusion) exposed no significant differences across these two distinct NOTCH1 expression groups ( $P > 0.05$ ). High NOTCH1 expression was linked with high expression of NOTCH1 legend (Dll1) ( $P < 0.001/\text{fold} > 2.5$ ). Our data also showed that high NOTCH1 mRNA is interrelated with heightened expression of positive regulator of the NOTCH signaling pathway (DTX1/DTX3). High NOTCH1 samples also showed high expression of TGRF-b associated protein SETBP1 ( $P < 0.001/\text{fold} > 2.5$ ) (Figure 1A). The level of NOTCH1 expression did not correlate with mortality {5/17 (29%) vs. 6/17; (35%)  $P > 0.05$ }. Low NOTCH1 expressers showed better OS {740 days vs. 579 days; log-rank  $P = < 0.007$ ; HR 6.3 (1.36-29.26)} **Conclusion:** Our pilot study identified high Notch1 expression through canonical pathway as an important poor prognostic marker among pediatric AML patients which is independent of conventional prognostic markers and can provide insights into novel potential therapeutic target. Our study has identified that high expression of the molecules linked with NOTCH1 pathway are an important poor prognostic marker among childhood AML patients. NOTCH1 expression also shows cross talk with several other signal transduction pathways especially TGFb / SETBP1 which are also linked with poor prognosis.

<https://doi.org/10.1016/j.htct.2022.09.1212>

#### OP 06

### EVALUATION OF COVID-19 FEAR AND QUALITY OF LIFE IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING THE COVID-19 PANDEMIC

Serhat Çelik<sup>1</sup>, Zeynep Tuğba Güven<sup>2</sup>, Funda İpekten<sup>3</sup>, Muzaffer Keklik<sup>2</sup>, Ali Ünal<sup>2</sup>, Leylagül Kaynar<sup>4</sup>

<sup>1</sup> Kırıkkale University Faculty of Medicine, Department of Hematology, Kırıkkale, Turkey

<sup>2</sup> Erciyes University Faculty of Medicine, Department of Hematology, Kayseri, Turkey

<sup>3</sup> Erciyes University Faculty of Medicine, Department of Biostatistics, Kayseri, Turkey

<sup>4</sup> Medipol Mega University Faculty of Medicine, Department of Hematology, İstanbul, Turkey

**Objective:** The coronavirus disease 2019 (COVID-19) pandemic has an impact on physical health, but also has effects on mental health. With the COVID-19 pandemic, the level of fear increases and fear triggers many psychological diseases such as depression. We aimed to determine the COVID-19 fear situation in hematopoietic stem cell transplantation (HSCT) patients and to examine its relationship with the quality of life. **Methodology:** In this prospective study, 64 patients who underwent HSCT during the pandemic (between 11 March 2020 and 31 December 2020) were included. The COVID-19 fear situation was evaluated with the Fear of COVID-19 Scale (FCV-19S). Quality of life was evaluated with the European Organization for Quality of Life Research and Treatment Core Questionnaire (EORTC QLQ-C30) (version 3). **Results:** The median FCV-19S score was 16.5 (12.0-22.0). The FCV-19S score was significantly higher in urban residents than rural residents (19.0 (15.0-23.5) vs 14.0 (9.0-22.0) ( $p = 0.44$ )). The general health score was  $59.64 \pm 20.04$ . The strongest positive correlation between fear level and quality of life was found in emotional function ( $r = 0.474$ ,  $p < 0.01$ ). In addition, a weak, significant, positive correlation was observed between role function, nausea-vomiting, pain, anorexia, and fear level. **Conclusion:** FCV-19S is a short, safe and valid tool that can be used to determine the COVID-19 fear level in vulnerable patient groups such as HSCT patients and to direct them to the necessary psycho-oncological support.

<https://doi.org/10.1016/j.htct.2022.09.1213>

#### OP 07

### UMBILICAL CORD BLOOD (UCB) AND BONE MARROW (BM) AS A SOURCE OF NATURAL KILLERS (NK) FOR KIR-ALLOREACTIVE ADOPTIVE IMMUNOTHERAPY (KIR-AI)

Kapitolina Melkova<sup>1</sup>, Gennady Frolov<sup>2</sup>, Zhanna Sharoyan<sup>1</sup>

<sup>1</sup> Guide to health

<sup>2</sup> Center of special studies Burnasyn medical biophysical center federal medical biology agency

**Objective:** NK are innate lymphoid cells with the ability to rapidly recognize and exhibit cytotoxicity toward tumor and virus infected cells in HLA-independent manner without prior activation. KIR-AI is the next promising step after KIR-alloreactive NMAC alloBM transplantation (not only in hematology). We evaluate NK amount, the balance of activating and inhibitory receptors (rp) of different sources, outcomes of KIR-AI UCB/BM. **Methodology:** NK UCB, BM, peripheral blood (PB) were evaluated by flow cytometry (CD3, 7, 16, 56, 94, NKG2A),